Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-interferon alpha-2a plus ribavirin in decompensated HCV-related cirrhosis
ChiCTR-ONRC-12002207Phase 4Completed
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Jan 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection and Cirrhosis (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoints: HCV RNA and Child-Pugh score. Started Jan 2005; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infectionCirrhosis
Beyond the preview
Go deeper on ChiCTR-ONRC-12002207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-12002207.